June 16, 23025 —GE HealthCare has launched the bkActiv S series, representing the next era of intraoperative ultrasound. The bkActiv S series is part of the bkPortfolio family of Active Imaging systems, designed to provide interventional guidance during urology, colorectal and pelvic floor procedures.  

June 23, 2025 — On June 23, 2025, Thermo Fisher Scientific announced it has been awarded a five-year, $94.5 million contract by the U.S. Department of Defense (DoD) to supply the Navy with a next-generation dosimetry system alongside updated radiation health and database management software.

June 19, 2025 – dGenThera, Inc., a biotechnology company pioneering theranostic molecular pairs, and Nusano, a physics company transforming the production of radioisotopes, have announced the signing of a letter of intent to provide dGenThera with access to high‑purity astatine‑211 (At‑211), a best‑in‑class alpha‑emitting isotope for cancer therapy.

June 23, 2025 — Susan G. Komen, the world’s leading breast cancer organization, recently announced it is awarding $10.8 million in new research grants that will help propel innovative science and deliver hope to those facing the disease. These research grants support 25 cutting-edge projects at 17 prestigious institutions — marking a powerful commitment to improving outcomes for people living with breast cancer today and in the future.

June 17, 2025 — Bayer has announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its investigational contrast agent gadoquatrane for contrast-enhanced magnetic resonance imaging of the CNS and other body regions in adults and pediatric patients including term neonates. The submitted dose is 0.04 mmol gadolinium per kilogram body weight. If approved, gadoquatrane would become the lowest dose macrocyclic GBCA available in the U.S., corresponding to a 60 percent reduction compared to macrocyclic GBCAs dosed at 0.1 mmol Gd/kg body weight.